In vitro and in vivo effects of zoledronic acid on senescence and senescence-associated secretory phenotype markers

Parinya Samakkarnthai,Dominik Saul,Lei Zhang,Zaira Aversa,Japneet Kaur,Tamar Tchkonia,Sundeep Khosla,Madison L. Doolittle,Jad G. Sfeir,Elizabeth J. Atkinson,James R. Edwards,Graham G. Russell,Robert J. Pignolo,James L. Kirkland,Laura J. Niedernhofer,David G. Monroe,Nathan K. Lebrasseur,Joshua N. Farr,Paul D. Robbins
DOI: https://doi.org/10.18632/aging.204701
2023-05-09
Aging
Abstract:In addition to reducing fracture risk, zoledronic acid has been found in some studies to decrease mortality in humans and extend lifespan and healthspan in animals. Because senescent cells accumulate with aging and contribute to multiple co-morbidities, the non-skeletal actions of zoledronic acid could be due to senolytic (killing of senescent cells) or senomorphic (inhibition of the secretion of the senescence-associated secretory phenotype [SASP]) actions. To test this, we first performed in...
cell biology,geriatrics & gerontology,gerontology
What problem does this paper attempt to address?